Developer docs
API playgroundTry for free, no card

Search company profiles

NGM Biopharmaceuticals

Full company profile

uuid0003of4

Namestring
NGM Biopharmaceuticals
Legal namestring
NGM Biopharmaceuticals, Inc.
Websiteurl
ngmbio.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

NGM Biopharmaceuticals is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California, focused on discovering and developing novel biotherapeutics. Founded in 2008 and operating as a wholly owned subsidiary of NGM Bio Holdings, Inc., the company applies a biology-centric drug discovery approach that combines interrogation of disease-associated biology with protein engineering expertise. NGM Bio is a recognized pioneer in GDF15 biology and discovered GDF15's cognate receptor GFRAL, a platform insight that anchors its lead asset NGM120.

The pipeline consists of three clinical-stage programs and one preclinical platform. NGM120 is a GFRAL/GDF15 antagonist monoclonal antibody in Phase 2 development for two indications: hyperemesis gravidarum (EMERALD Phase 2, with first patient dosed in February 2025 at UK and Australian sites) and cancer cachexia (Phase 2 proof-of-concept). Aldafermin, an engineered FGF19 analog, is advancing toward a potential registrational trial in primary sclerosing cholangitis. NGM707 (dual ILT2/ILT4 antagonist) completed Phase 1/2 enrollment in advanced solid tumors, and NGM936 is a bispecific T cell engager targeting ILT3 in monocytic acute myeloid leukemia. The preclinical RI-ACT platform develops bispecific rapidly internalizing ADCs for solid tumors.

NGM Bio is pre-revenue and finances operations through venture capital, having raised approximately $540 million+ across multiple prior rounds and a $122 million Series A led by The Column Group in July 2024. The company employs 101-250 staff and is led by CEO Diana Peng Bockus and CMO Wendy Yeh, M.D. (appointed February 2025). Commercial revenue is expected to flow through traditional pharmaceutical channels to hospitals and specialty pharmacies once products are approved, with no pricing model yet established and no approved therapies on market.

Short descriptiontext

NGM Biopharmaceuticals is a privately held, clinical-stage biotechnology company developing monoclonal antibodies for rare diseases, including NGM120 (a GFRAL/GDF15 antagonist) for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, rare disease therapeutics, monoclonal antibody development, antibody drug conjugates, novel biologics discovery
Industry1 code
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Expects to generate revenue through sales of approved pharmaceutical products upon successful completion of clinical trials and regulatory approval. Currently developing NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis.

ngmbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel biotherapeutics, primarily monoclonal antibodies and antibody-drug conjugates, for rare diseases with high unmet medical need. Its pipeline includes NGM120 (a GDF15/GFRAL antagonist antibody in Phase 2 trials for hyperemesis gravidarum and cancer cachexia), aldafermin (an FGF19 analog for primary sclerosing cholangitis), NGM707 (dual ILT2/ILT4 antagonist for solid tumors), NGM936 (bispecific T cell engager for acute myeloid leukemia), and the preclinical RI-ACT bispecific ADC platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • NGM120 generally well-tolerated in over 200 participants treated in clinical trials to date
+4 more records
Product overview1 text field

NGM Biopharmaceuticals is a clinical-stage, privately held biotechnology company developing a portfolio of novel therapeutics. The core products include NGM120 (GFRAL antagonist antibody in Phase 2 for Hyperemesis Gravidarum and Cancer Cachexia), aldafermin (FGF19 analog for Primary Sclerosing Cholangitis), NGM707 (dual ILT2/ILT4 antagonist for solid tumors), and NGM936 (bispecific T cell engager for hematological malignancies). Preclinical programs include RI-ACT™ bispecific ADC platform for solid tumors. The company's biology-centric drug discovery approach integrates disease biology interrogation with protein engineering expertise.

Product and service5 records
1NGM120
CategoryMonoclonal antibody therapeutic
2Aldafermin
CategoryEngineered protein therapeutic
3NGM707
CategoryMonoclonal antibody therapeutic
4NGM936
CategoryBispecific antibody therapeutic
5RI-ACT (Bispecific Rapidly Internalizing ADC Cancer Therapeutics)
CategoryAntibody drug conjugate platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology-focused biotech based in San Francisco that has developed multiple antibody therapeutics through partnerships with major pharma. Comparable to NGM Bio as a Bay Area antibody developer with similar management pedigree (Wendy Yeh joined NGM from Vir) and parallel clinical development model.

TypeDirect peer
Description

Liver disease-focused biotech that developed obeticholic acid for primary biliary cholangitis and explored PSC. Directly comparable to NGM Bio's aldafermin program given shared focus on cholangiopathies and the registrational/regulatory pathway for rare liver diseases.

TypeDirect peer
Description

Clinical-stage biotech that advanced rare disease therapeutics (geographic atrophy, PNH) from Phase 2 through approval using novel biologics mechanisms. Comparable to NGM Bio as a developer of biologic therapeutics for rare indications with limited treatment options and similar pathway to first-in-class approval.

4Principia Biopharma
TypeEmerging player
Description

Bay Area biotech developing small-molecule and biologic therapies for immunology; acquired by Sanofi in 2020. Wendy Yeh's prior tenure at Principia makes it a strong people/operating-model peer, and its exit via acquisition illustrates one potential outcome path for NGM Bio.

TypeDirect peer
Description

Clinical-stage biotech focused on immune-mediated diseases, acquired by Sanofi in 2023. Comparable to NGM Bio given similar pre-revenue clinical-stage model and eventual pharma acquisition as a value-realization pathway for rare disease assets.

TypeDirect peer
Description

Clinical-stage oncology biotech developing masked antibody therapeutics including probody-drug conjugates. Comparable to NGM Bio as a developer of differentiated antibody engineering platforms targeting oncology with platform optionality beyond single assets.

TypeDirect peer
Description

Clinical-stage biotech developing next-generation antibody-drug conjugates with novel payload and linker technologies. Directly comparable to NGM's RI-ACT ADC platform given shared focus on improving ADC internalization and tumor selectivity.

TypeDirect peer
Description

Clinical-stage oncology biotech developing immuno-oncology combinations including anti-TIGIT antibodies. Comparable to NGM Bio's NGM707 (immuno-oncology antibody) program given similar mechanism exploration of immune checkpoint blockade for solid tumors.

TypeEmerging player
Description

Clinical-stage precision oncology company that was acquired by Bristol-Myers Squibb in 2024. Comparable to NGM Bio's oncology development model, particularly for NGM707 and NGM936 programs targeting hematologic malignancies and solid tumors, with a recent exit precedent.

TypeBroad incumbent
Description

Established ADC-focused biotech acquired by AbbVie in 2024. Comparable to NGM's RI-ACT ADC efforts given shared focus on antibody-drug conjugate platforms, and serves as a recent benchmark for ADC-platform M&A valuations.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NGM Biopharmaceuticals

Rare Disease Biopharmaceuticalsngmbio.com

NGM Biopharmaceuticals is a privately held, clinical-stage biotechnology company developing monoclonal antibodies for rare diseases, including NGM120 (a GFRAL/GDF15 antagonist) for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis.

What NGM Biopharmaceuticals does

NGM Biopharmaceuticals is a privately held, clinical-stage biotechnology company headquartered in South San Francisco, California, focused on discovering and developing novel biotherapeutics. Founded in 2008 and operating as a wholly owned subsidiary of NGM Bio Holdings, Inc., the company applies a biology-centric drug discovery approach that combines interrogation of disease-associated biology with protein engineering expertise. NGM Bio is a recognized pioneer in GDF15 biology and discovered GDF15's cognate receptor GFRAL, a platform insight that anchors its lead asset NGM120.

The pipeline consists of three clinical-stage programs and one preclinical platform. NGM120 is a GFRAL/GDF15 antagonist monoclonal antibody in Phase 2 development for two indications: hyperemesis gravidarum (EMERALD Phase 2, with first patient dosed in February 2025 at UK and Australian sites) and cancer cachexia (Phase 2 proof-of-concept). Aldafermin, an engineered FGF19 analog, is advancing toward a potential registrational trial in primary sclerosing cholangitis. NGM707 (dual ILT2/ILT4 antagonist) completed Phase 1/2 enrollment in advanced solid tumors, and NGM936 is a bispecific T cell engager targeting ILT3 in monocytic acute myeloid leukemia. The preclinical RI-ACT platform develops bispecific rapidly internalizing ADCs for solid tumors.

NGM Bio is pre-revenue and finances operations through venture capital, having raised approximately $540 million+ across multiple prior rounds and a $122 million Series A led by The Column Group in July 2024. The company employs 101-250 staff and is led by CEO Diana Peng Bockus and CMO Wendy Yeh, M.D. (appointed February 2025). Commercial revenue is expected to flow through traditional pharmaceutical channels to hospitals and specialty pharmacies once products are approved, with no pricing model yet established and no approved therapies on market.

NGM Biopharmaceuticals firmographics

Firmographics
Name
NGM Biopharmaceuticals
Legal name
NGM Biopharmaceuticals, Inc.
Website
https://ngmbio.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
NGM Biopharmaceuticals is a privately held, clinical-stage biotechnology company developing monoclonal antibodies for rare diseases, including NGM120 (a GFRAL/GDF15 antagonist) for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis.
Ownership category
akta.pro rank

NGM Biopharmaceuticals industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Clinical-stage biopharmaceuticals
  • Rare disease therapeutics
  • Monoclonal antibody development
  • Antibody drug conjugates
  • Novel biologics discovery

Where NGM Biopharmaceuticals is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NGM Biopharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Expects to generate revenue through sales of approved pharmaceutical products upon successful completion of clinical trials and regulatory approval. Currently developing NGM120 for hyperemesis gravidarum and cancer cachexia, and aldafermin for primary sclerosing cholangitis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

NGM Biopharmaceuticals product offering

Product offering

Core offering

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel biotherapeutics, primarily monoclonal antibodies and antibody-drug conjugates, for rare diseases with high unmet medical need. Its pipeline includes NGM120 (a GDF15/GFRAL antagonist antibody in Phase 2 trials for hyperemesis gravidarum and cancer cachexia), aldafermin (an FGF19 analog for primary sclerosing cholangitis), NGM707 (dual ILT2/ILT4 antagonist for solid tumors), NGM936 (bispecific T cell engager for acute myeloid leukemia), and the preclinical RI-ACT bispecific ADC platform.

Product overview

NGM Biopharmaceuticals is a clinical-stage, privately held biotechnology company developing a portfolio of novel therapeutics. The core products include NGM120 (GFRAL antagonist antibody in Phase 2 for Hyperemesis Gravidarum and Cancer Cachexia), aldafermin (FGF19 analog for Primary Sclerosing Cholangitis), NGM707 (dual ILT2/ILT4 antagonist for solid tumors), and NGM936 (bispecific T cell engager for hematological malignancies). Preclinical programs include RI-ACT™ bispecific ADC platform for solid tumors. The company's biology-centric drug discovery approach integrates disease biology interrogation with protein engineering expertise.

Differentiator

Problem solved

Functional benefit

Products and services

  • NGM120
  • Aldafermin
  • NGM707
  • NGM936
  • RI-ACT (Bispecific Rapidly Internalizing ADC Cancer Therapeutics)

Quantifiable outcome

  • NGM120 generally well-tolerated in over 200 participants treated in clinical trials to date
  • +4 more outcomes

Companies that use NGM Biopharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

NGM Biopharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NGM Biopharmaceuticals partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

NGM Biopharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Vir Biotechnology: Clinical-stage immunology-focused biotech based in San Francisco that has developed multiple antibody therapeutics through partnerships with major pharma. Comparable to NGM Bio as a Bay Area antibody developer with similar management pedigree (Wendy Yeh joined NGM from Vir) and parallel clinical development model.
  • Intercept Pharmaceuticals: Liver disease-focused biotech that developed obeticholic acid for primary biliary cholangitis and explored PSC. Directly comparable to NGM Bio's aldafermin program given shared focus on cholangiopathies and the registrational/regulatory pathway for rare liver diseases.
  • Apellis Pharmaceuticals: Clinical-stage biotech that advanced rare disease therapeutics (geographic atrophy, PNH) from Phase 2 through approval using novel biologics mechanisms. Comparable to NGM Bio as a developer of biologic therapeutics for rare indications with limited treatment options and similar pathway to first-in-class approval.
  • Provention Bio: Clinical-stage biotech focused on immune-mediated diseases, acquired by Sanofi in 2023. Comparable to NGM Bio given similar pre-revenue clinical-stage model and eventual pharma acquisition as a value-realization pathway for rare disease assets.
  • CytomX Therapeutics: Clinical-stage oncology biotech developing masked antibody therapeutics including probody-drug conjugates. Comparable to NGM Bio as a developer of differentiated antibody engineering platforms targeting oncology with platform optionality beyond single assets.
  • Mersana Therapeutics: Clinical-stage biotech developing next-generation antibody-drug conjugates with novel payload and linker technologies. Directly comparable to NGM's RI-ACT ADC platform given shared focus on improving ADC internalization and tumor selectivity.
  • Arcus Biosciences: Clinical-stage oncology biotech developing immuno-oncology combinations including anti-TIGIT antibodies. Comparable to NGM Bio's NGM707 (immuno-oncology antibody) program given similar mechanism exploration of immune checkpoint blockade for solid tumors.

Emerging players

  • Principia Biopharma: Bay Area biotech developing small-molecule and biologic therapies for immunology; acquired by Sanofi in 2020. Wendy Yeh's prior tenure at Principia makes it a strong people/operating-model peer, and its exit via acquisition illustrates one potential outcome path for NGM Bio.
  • Mirati Therapeutics: Clinical-stage precision oncology company that was acquired by Bristol-Myers Squibb in 2024. Comparable to NGM Bio's oncology development model, particularly for NGM707 and NGM936 programs targeting hematologic malignancies and solid tumors, with a recent exit precedent.

Broad incumbents

  • ImmunoGen: Established ADC-focused biotech acquired by AbbVie in 2024. Comparable to NGM's RI-ACT ADC efforts given shared focus on antibody-drug conjugate platforms, and serves as a recent benchmark for ADC-platform M&A valuations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NGM Biopharmaceuticals social profiles

Digital presence

NGM Biopharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NGM Biopharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

NGM Biopharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NGM Biopharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NGM Biopharmaceuticals

What does NGM Biopharmaceuticals do?

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops novel biotherapeutics, primarily monoclonal antibodies and antibody-drug conjugates, for rare diseases with high unmet medical need. Its pipeline includes NGM120 (a GDF15/GFRAL antagonist antibody in Phase 2 trials for hyperemesis gravidarum and cancer cachexia), aldafermin (an FGF19 analog for primary sclerosing cholangitis), NGM707 (dual ILT2/ILT4 antagonist for solid tumors), NGM936 (bispecific T cell engager for acute myeloid leukemia), and the preclinical RI-ACT bispecific ADC platform.

Is NGM Biopharmaceuticals a public or private company?

NGM Biopharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was NGM Biopharmaceuticals founded?

NGM Biopharmaceuticals was founded in 2008. It employs 51 to 100 people.

Where is NGM Biopharmaceuticals based?

NGM Biopharmaceuticals is headquartered in South San Francisco, United States, in the North America region.

How does NGM Biopharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are NGM Biopharmaceuticals's main competitors?

Direct peers on record are Vir Biotechnology, Intercept Pharmaceuticals, Apellis Pharmaceuticals, Provention Bio, CytomX Therapeutics, Mersana Therapeutics and Arcus Biosciences. Emerging players are Principia Biopharma and Mirati Therapeutics. ImmunoGen is listed as a broad incumbent.

Does NGM Biopharmaceuticals have an API?

No public API is recorded for NGM Biopharmaceuticals.

What industry is NGM Biopharmaceuticals in?

NGM Biopharmaceuticals's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales